Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 2:58 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Avidity Partners Management LP | 3,825,000 8.200% | 720,000 (+23.19%) | Filing History |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 2,401,037 5.100% | 2,401,037 (New Position) | Filing History |
| 2023-02-13 10:54 am Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Alkeon Capital Management LLC | 3,243,915 6.900% | 764,244 (+30.82%) | Filing History |
| 2023-02-10 11:27 am Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 3,340,174 7.100% | 176,552 (+5.58%) | Filing History |
| 2023-02-07 4:31 pm Sale | 2022-12-30 | 13G | Akero Therapeutics, Inc. AKRO | GOLDMAN SACHS GROUP INC GS | 474,564 1.000% | -1,301,628 (-73.28%) | Filing History |
| 2023-02-06 2:43 pm Sale | 2022-12-30 | 13G | Akero Therapeutics, Inc. AKRO | Wellington Management Group LLP | 876,099 1.870% | -1,000,712 (-53.32%) | Filing History |
| 2023-02-03 2:06 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | STATE STREET CORP STT | 2,500,969 5.350% | 2,500,969 (New Position) | Filing History |
| 2023-02-03 12:09 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | BlackRock Inc. BLK | 2,758,529 5.900% | 494,286 (+21.83%) | Filing History |
| 2022-12-05 4:40 pm Sale | 2022-12-01 | 13G | Akero Therapeutics, Inc. AKRO | Skorpios Trust | 3,271,829 7.000% | -1,636,000 (-33.33%) | Filing History |
| 2022-11-09 2:21 pm Purchase | 2021-10-31 | 13G | Akero Therapeutics, Inc. AKRO | BlackRock Inc. BLK | 2,264,243 4.900% | 320,121 (+16.47%) | Filing History |
| 2022-09-16 10:16 am Purchase | 2022-09-15 | 13G | Akero Therapeutics, Inc. AKRO | Avidity Partners Management LP | 3,105,000 6.900% | 3,105,000 (New Position) | Filing History |
| 2022-09-15 5:00 pm Sale | 2022-09-13 | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 714,000 1.900% | -1,601,893 (-69.17%) | Filing History |
| 2022-06-28 4:19 pm Purchase | 2022-06-17 | 13G | Akero Therapeutics, Inc. AKRO | PFIZER INC PFE | 2,525,252 6.700% | 2,525,252 (New Position) | Filing History |
| 2022-02-14 5:07 pm Sale | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Redmile Group, LLC | 1,602,285 4.600% | -720,272 (-31.01%) | Filing History |
| 2022-02-14 4:26 pm Purchase | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Point72 Asset Management, L.P. | 1,760,248 5.000% | 8,685 (+0.50%) | Filing History |
| 2022-02-11 8:25 pm Purchase | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Alkeon Capital Management LLC | 2,479,671 7.100% | 192,041 (+8.39%) | Filing History |
| 2022-02-11 5:03 pm Sale | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI, L.P. | 1,963,529 5.600% | -242,883 (-11.01%) | Filing History |
| 2022-02-10 2:07 pm Sale | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 3,163,622 9.100% | -329,797 (-9.44%) | Filing History |
| 2022-02-08 4:19 pm Purchase | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | GOLDMAN SACHS GROUP INC GS | 1,776,192 5.100% | 1,776,192 (New Position) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | BlackRock Inc. BLK | 1,944,122 5.600% | 1,944,122 (New Position) | Filing History |